Starting rare

Inozyme Pharma Inc. plans to use its $49 million series A round to demonstrate human proof of concept for its lead candidate in a pair of rare calcification disorders. But the newco and its lead investor Longitude Capital are also eyeing applications in more prevalent, chronic diseases.

New Enterprise Associates, Novo Ventures and Sanofi Ventures participated in the A round, which closed on Nov. 15. ...